TexRAD bought by Feedback plc as part of £800,000 deal
University of Sussex spinout company TexRAD has been bought by medical imaging tools specialists Feedback plc, as part of a deal worth almost £800,000.Read more
TexRAD is a software application that analyses the textures in existing radiological scans to assist the clinician in assessing the prognosis of patients with cancer. It is currently applicable to colorectal, breast, lung, prostate, oesophagus and renal cancers.
For Imaging and PACS OEMs:
"The preliminary TexRAD results were impressive: I was able to identify an invasive breast cancer focus within larger area of pre-operative, non-invasive disease."
- Dr Olga Strukowska, Consultant Radiologist of the Western Sussex Hospitals Trust, Worthing
"TexRAD provides unique tumor information, which in addition to standard morphological assessment, could improve therapeutic assessment in renal cancer treated with tyrosine kinase inhibitors. The preliminary results are encouraging for its use as a predictive biomarker in this clinical context.
- Dr Vicky Goh, Consultant Radiologist at Mount Vernon Hospital, Northwood
"TexRAD assists clinical decision-making by predicting the risk of disease and assessing the prognosis for cancer patients.
- Professor Ken Miles, Consultant Radiologist and TexRAD's lead clinical advisor